Subcutaneous efalizumab is not effective in the treatment of alopecia areata

Vera H. Price, Maria K Hordinsky, Elise A. Olsen, Janet L. Roberts, Elaine C. Siegfried, Elyse S. Rafal, Neil J. Korman, Basel Altrabulsi, Hoi M. Leung, Marvin R. Garovoy, Ivor Caro, David A. Whiting

Research output: Contribution to journalArticlepeer-review

47 Scopus citations


Background: Alopecia areata (AA) is a T-cell-mediated autoimmune disease. Efalizumab is a T-cell-targeted therapy approved for the treatment of psoriasis. Objective: To assess the efficacy and safety of efalizumab in the treatment of moderate-to-severe AA. Methods: Sixty-two patients were enrolled into this phase II, placebo-controlled trial. The trial consisted of three 12-week periods-a double-blind treatment period, an open-label efalizumab treatment period, and a safety follow-up. Results: There were no statistical differences between treatment groups in percent hair regrowth, quality-of-life measures, or changes in biologic markers of disease severity after 12 or 24 weeks. In both groups, there was an approximately 8% response rate for hair regrowth (at 12 weeks). Efalizumab was well tolerated. Limitations: Numbers were too small for certain analyses. Conclusion: A 3- to 6-month trial of efalizumab was not effective in promoting hair regrowth in this small cohort of patients with moderate-to-severe AA.

Original languageEnglish (US)
Pages (from-to)395-402
Number of pages8
JournalJournal of the American Academy of Dermatology
Issue number3
StatePublished - Mar 2008

Bibliographical note

Funding Information:
Supported by Genentech, Inc.

Copyright 2008 Elsevier B.V., All rights reserved.

Fingerprint Dive into the research topics of 'Subcutaneous efalizumab is not effective in the treatment of alopecia areata'. Together they form a unique fingerprint.

Cite this